Company Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 13:48:13 2026-03-13 EDT			5-day change	1st Jan Change
116.68 ^USD	+0.67%		+0.60%	+10.67%

03-12	Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating	MT
03-10	Merck's Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says	MT

Business description: Merck & Co., Inc.

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:

- sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;

- sale of vaccines (20%);

- sale of animal health products (9.2%);

- other (1.4%).

Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Number of employees: 74,000

Sales by Activity: Merck & Co., Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Pharmaceutical	42.75B	52B	53.58B	57.4B	58.14B
Animal Health	5.57B	5.55B	5.62B	5.88B	6.35B
Unallocated Other Revenues	382M	1.73B	907M	891M	515M

See all business segments

Geographical breakdown of sales: Merck & Co., Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	22.42B	27.21B	28.48B	32.28B	36.51B
Europe, Middle East and Africa	13.34B	14.49B	13.25B	14.04B	14.58B
Latin America	2.21B	2.58B	3.09B	3.46B	3.41B
Asia Pacific (other than Japan and China)	2.41B	3.61B	3.22B	3.06B	2.98B
Other	1.22B	2.57B	2.1B	2.56B	2.88B
Japan	2.73B	3.63B	3.16B	3.28B	2.71B
China	4.38B	5.19B	6.8B	5.49B	1.94B

See all geographic segments

Executive Committee: Merck & Co., Inc.

Manager	Title	Age	Since
Robert Davis CEO	Chief Executive Officer	59	2021-06-30
Caroline Litchfield DFI	Director of Finance/CFO	57	2021-03-31
Dave Williams CTO	Chief Tech/Sci/R&D Officer	57	2020-07-31
Peter Dannenbaum IRC	Investor Relations Contact	-	2017-06-30
Joseph Romanelli IRC	Investor Relations Contact	52	1995-12-31

See MERCK & CO., INC. governance

Composition of the Board of Directors: Merck & Co., Inc.

Director	Title	Age	Since
Tom Glocer BRD	Director/Board Member	65	2007-11-26
Patricia Russo BRD	Director/Board Member	73	1995-08-31
Robert Davis CHM	Chairman	59	2022-11-30
Pamela Craig BRD	Director/Board Member	69	2015-08-31
Paul Rothman BRD	Director/Board Member	67	2015-08-31
Inge Thulin BRD	Director/Board Member	71	2018-02-28
Mary Coe BRD	Director/Board Member	58	2019-03-17
Kathy Warden BRD	Director/Board Member	53	2020-03-15
Christine Seidman BRD	Director/Board Member	72	2020-03-15
Risa Lavizzo-Mourey BRD	Director/Board Member	71	2020-05-25

Composition of the Board of Directors

Shareholders: Merck & Co., Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.29 %	254,322,763	10.29 %	31 490 M $
BlackRock Advisors LLC 6.509 %	160,933,559	6.509 %	19 927 M $
STATE STREET CORPORATION 4.855 %	120,040,168	4.855 %	14 863 M $
Wellington Trust Co., NA 3.496 %	86,435,458	3.496 %	10 702 M $
Geode Capital Management LLC 2.429 %	60,047,984	2.429 %	7 435 M $

Name	Equities	%	Valuation
Caixa DTVM SA 0.00109 %	215,530	0.00109 %	3 M $
Safra Asset CTVM SA (Investment Management) 0.000294 %	58,100	0.000294 %	883 903 $
XP Allocation Asset Management Ltda. 0.000027 %	5,293	0.000027 %	80 525 $
E2M Investimentos Ltda. 0.000004 %	700	0.000004 %	10 649 $

List of MERCK & CO., INC. shareholders

Holdings: Merck & Co., Inc.

Name	Equities	%	Valuation
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. 8.26%	13,443,693	8.26%	666 M $
PERSONALIS, INC. 15.84%	14,044,943	15.84%	127 M $
MODERNA, INC. 0.58%	2,308,190	0.58%	124 M $
KYMERA THERAPEUTICS, INC. 0.98%	772,165	0.98%	71 M $
ENTRADA THERAPEUTICS, INC. 4.55%	1,739,768	4.55%	21 M $
ALECTOR, INC. 3.21%	3,545,719	3.21%	9 M $
SUTRO BIOPHARMA, INC. 1.66%	272,351	1.66%	6 M $
EVAXION A/S 19.22%	1,214,126	19.22%	4 M $
VIRIDIAN THERAPEUTICS, INC. 0.1%	93,414	0.1%	3 M $
XILIO THERAPEUTICS, INC. 2.02%	1,483,758	2.02%	783 424 $

Company details: Merck & Co., Inc.

Merck & Co., Inc.

126 East Lincoln Avenue

07065, Rahway

+908 740 4000

http://www.merck.com

Group companies: Merck & Co., Inc.

Name	Category and Sector
MSD Sharp & Dohme GmbH MSD Sharp & Dohme GmbH Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceutical products & vaccines	Pharmaceuticals: Major
Merck Sharp & Dohme LLC Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company	Pharmaceuticals: Major
Merck Sharp & Dohme LLC Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company	Pharmaceuticals: Major
MSD Finance BV MSD Finance BV MiscellaneousMiscellaneous Functions as an investment holding company	Miscellaneous
Merck Sharp & Dohme Finance Europe Ltd. Merck Sharp & Dohme Finance Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Provides business support services	Miscellaneous Commercial Services

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MERCK & CO., INC.	+0.67%	+0.60%	+23.00%	+10.18%	287B
ELI LILLY AND COMPANY	+1.34%	-0.14%	+23.37%	+204.78%	873B
JOHNSON & JOHNSON	+0.49%	+1.06%	+49.06%	+58.73%	583B
ABBVIE INC.	-1.01%	-3.32%	+5.16%	+46.41%	398B
ROCHE HOLDING AG	+0.79%	-6.01%	+5.81%	+21.36%	324B
ASTRAZENECA PLC	+0.11%	-0.83%	+21.02%	+34.57%	297B
NOVARTIS AG	+0.43%	-1.54%	+25.20%	+62.42%	294B
AMGEN INC.	+0.02%	-0.47%	+17.64%	+57.73%	198B
GILEAD SCIENCES, INC.	+0.90%	+1.15%	+28.43%	+83.10%	180B
PFIZER INC.	-0.43%	-1.28%	+4.32%	-33.00%	153B
Average	+0.25%	-1.71%	+20.30%	+54.63%	358.81B
Weighted average by Cap.	+0.42%	-1.63%	+22.99%	+81.21%